CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients.
Abatacept
Autoimmune
CTLA4-Ig
M1–M2 polarisation
Macrophages
Monocytes
Rheumatoid arthritis
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
24 12 2021
24 12 2021
Historique:
received:
26
07
2021
accepted:
03
12
2021
entrez:
25
12
2021
pubmed:
26
12
2021
medline:
11
3
2022
Statut:
epublish
Résumé
In rheumatoid arthritis (RA), macrophages play an important role in modulating the immunoinflammatory response through their polarisation into "classically" (M1) or "alternatively activated" (M2) phenotypes. In RA, CTLA4-Ig (abatacept) reduces the inflammatory activity of macrophages by interacting with the costimulatory molecule CD86. The study aimed to investigate the efficacy of CTLA4-Ig treatment to induce an M2 phenotype both in M1-polarised monocyte-derived macrophages (MDMs) obtained from healthy subjects (HS) and in cultured MDMs obtained from active RA patients. Cultured MDMs were obtained from peripheral blood mononuclear cells of 7 active RA patients and from 10 HS after stimulation with phorbol myristate acetate (5 ng/mL) for 24 h. HS-MDMs were then stimulated with lipopolysaccharide (LPS, 1 mg/mL) for 4 h to induce M1-MDMs. M1-MDMs and RA-MDMs were treated with CTLA4-Ig (100 μM and 500 μM) for 3, 12, 24, and 48 h. The gene expression of CD80, CD86, and TLR4 (M1 markers); CD163, CD204, and CD206 (surface M2 markers); and MerTK (functional M2 marker) was evaluated by qRT-PCR. The protein synthesis of surface M2 markers was investigated by Western blotting. The statistical analysis was performed by the Wilcoxon t-test. In LPS-induced HS-M1-MDMs, CTLA4-Ig 100 μM and 500 μM significantly downregulated the gene expression of M1 markers (3 h p<0.01 for all molecules; 12 h p<0.05 for TLR4 and CD86) and significantly upregulated that of M2 markers, primarily after 12 h of treatment (CD163: p < 0.01 and p < 0.05; CD206: p < 0.05 and p < 0.01; CD204: p < 0.05 by 100 mg/mL). Moreover, in these cells, CTLA4-Ig 500 μM increased the protein synthesis of surface M2 markers (p < 0.05). Similarly, in RA-MDMs, the CTLA4-Ig treatment significantly downregulated the gene expression of M1 markers at both concentrations primarily after 12 h (p < 0.05). Furthermore, both concentrations of CTLA4-Ig significantly upregulated the gene expression of CD206 (after 3 h of treatment; p < 0.05), CD163, and MerTK (after 12 h of treatment, p < 0.05), whereas CD204 gene expression was significantly upregulated by the high concentration of CTLA4-Ig (p < 0.05). The protein synthesis of all surface markers was increased primarily by CTLA4-Ig 500 μM, significantly for CD204 and CD206 after 24 h of treatment (p < 0.05). CTLA4-Ig treatment seems to induce the in vitro shift from M1 to M2 macrophages, of both HS-M1-MDMs and RA-MDMs, as observed by the significant downregulation exerted on selected M1 markers and the upregulation of selected M2 markers suggesting an additional mechanism for its modulation of the RA inflammatory process.
Sections du résumé
BACKGROUND
In rheumatoid arthritis (RA), macrophages play an important role in modulating the immunoinflammatory response through their polarisation into "classically" (M1) or "alternatively activated" (M2) phenotypes. In RA, CTLA4-Ig (abatacept) reduces the inflammatory activity of macrophages by interacting with the costimulatory molecule CD86. The study aimed to investigate the efficacy of CTLA4-Ig treatment to induce an M2 phenotype both in M1-polarised monocyte-derived macrophages (MDMs) obtained from healthy subjects (HS) and in cultured MDMs obtained from active RA patients.
METHODS
Cultured MDMs were obtained from peripheral blood mononuclear cells of 7 active RA patients and from 10 HS after stimulation with phorbol myristate acetate (5 ng/mL) for 24 h. HS-MDMs were then stimulated with lipopolysaccharide (LPS, 1 mg/mL) for 4 h to induce M1-MDMs. M1-MDMs and RA-MDMs were treated with CTLA4-Ig (100 μM and 500 μM) for 3, 12, 24, and 48 h. The gene expression of CD80, CD86, and TLR4 (M1 markers); CD163, CD204, and CD206 (surface M2 markers); and MerTK (functional M2 marker) was evaluated by qRT-PCR. The protein synthesis of surface M2 markers was investigated by Western blotting. The statistical analysis was performed by the Wilcoxon t-test.
RESULTS
In LPS-induced HS-M1-MDMs, CTLA4-Ig 100 μM and 500 μM significantly downregulated the gene expression of M1 markers (3 h p<0.01 for all molecules; 12 h p<0.05 for TLR4 and CD86) and significantly upregulated that of M2 markers, primarily after 12 h of treatment (CD163: p < 0.01 and p < 0.05; CD206: p < 0.05 and p < 0.01; CD204: p < 0.05 by 100 mg/mL). Moreover, in these cells, CTLA4-Ig 500 μM increased the protein synthesis of surface M2 markers (p < 0.05). Similarly, in RA-MDMs, the CTLA4-Ig treatment significantly downregulated the gene expression of M1 markers at both concentrations primarily after 12 h (p < 0.05). Furthermore, both concentrations of CTLA4-Ig significantly upregulated the gene expression of CD206 (after 3 h of treatment; p < 0.05), CD163, and MerTK (after 12 h of treatment, p < 0.05), whereas CD204 gene expression was significantly upregulated by the high concentration of CTLA4-Ig (p < 0.05). The protein synthesis of all surface markers was increased primarily by CTLA4-Ig 500 μM, significantly for CD204 and CD206 after 24 h of treatment (p < 0.05).
CONCLUSIONS
CTLA4-Ig treatment seems to induce the in vitro shift from M1 to M2 macrophages, of both HS-M1-MDMs and RA-MDMs, as observed by the significant downregulation exerted on selected M1 markers and the upregulation of selected M2 markers suggesting an additional mechanism for its modulation of the RA inflammatory process.
Identifiants
pubmed: 34952630
doi: 10.1186/s13075-021-02691-9
pii: 10.1186/s13075-021-02691-9
pmc: PMC8709961
doi:
Substances chimiques
CTLA-4 Antigen
0
CTLA4 protein, human
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
306Informations de copyright
© 2021. The Author(s).
Références
Ann Rheum Dis. 2010 May;69(5):935-6
pubmed: 19700394
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
PLoS One. 2014 Oct 17;9(10):e109775
pubmed: 25329467
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Autoimmun Rev. 2019 Nov;18(11):102397
pubmed: 31520798
Ann N Y Acad Sci. 1999 Jun 22;876:32-41; discussion 41-2
pubmed: 10415591
Clin Exp Immunol. 2014 Sep;177(3):630-40
pubmed: 24773026
Biochem Biophys Res Commun. 2013 Aug 16;438(1):103-9
pubmed: 23872146
Nat Rev Rheumatol. 2016 Aug;12(8):472-85
pubmed: 27383913
Osteoarthritis Cartilage. 2020 May;28(5):555-561
pubmed: 31982565
Mediators Inflamm. 2015;2015:816460
pubmed: 26089604
Arch Immunol Ther Exp (Warsz). 2003;51(6):421-8
pubmed: 14692664
Mol Med Rep. 2016 Nov;14(5):4505-4510
pubmed: 27748869
J Inflamm Res. 2016 Feb 09;9:1-11
pubmed: 26929657
Nat Med. 2020 Aug;26(8):1295-1306
pubmed: 32601335
N Engl J Med. 2020 Oct 15;383(16):1511-1521
pubmed: 33053283
Clin Exp Rheumatol. 2016 May-Jun;34(3):500-6
pubmed: 26940199
Scand J Immunol. 2014 May;79(5):305-14
pubmed: 24521472
PLoS One. 2015 Apr 10;10(4):e0122198
pubmed: 25860138
Nat Rev Immunol. 2007 Jun;7(6):429-42
pubmed: 17525752
Curr Opin Rheumatol. 2018 May;30(3):295-300
pubmed: 29401118
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Eur J Immunol. 1996 Nov;26(11):2758-63
pubmed: 8921966
Arthritis Res Ther. 2009;11(6):R176
pubmed: 19930661
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Rheumatol. 2013 May;40(5):738-40
pubmed: 23637380
Reumatismo. 2011;63(2):80-5
pubmed: 21776443
Ann Rheum Dis. 2018 Dec;77(12):1842-1845
pubmed: 30012643
Ann Rheum Dis. 2018 Feb;77(2):300-308
pubmed: 29191820
Crit Rev Immunol. 2012;32(6):463-88
pubmed: 23428224
Inflammation. 2015 Dec;38(6):2067-75
pubmed: 26063186
Respir Res. 2018 Sep 24;19(1):186
pubmed: 30249259
Cell. 2010 Mar 19;140(6):871-82
pubmed: 20303877
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Drugs. 2017 Jul;77(11):1221-1233
pubmed: 28608166
Clin Exp Rheumatol. 2013 Nov-Dec;31(6):943-6
pubmed: 24295474
J Autoimmun. 2019 Jul;101:145-152
pubmed: 31054942
Front Immunol. 2015 May 05;6:212
pubmed: 25999950
J Autoimmun. 2019 May;99:24-32
pubmed: 30679006
Int Immunopharmacol. 2017 Sep;50:345-352
pubmed: 28750350
BMC Res Notes. 2011 Oct 20;4:427
pubmed: 22011438
Immunol Cell Biol. 2008 Jul;86(5):398-408
pubmed: 18392044
J Immunol Res. 2018 Jan 14;2018:8917804
pubmed: 29507865
Expert Rev Clin Immunol. 2016;12(4):417-25
pubmed: 26679631
Life Sci. 2019 May 1;224:222-231
pubmed: 30928403
Arthritis Res Ther. 2017 Nov 2;19(1):245
pubmed: 29096690
Cell Prolif. 2020 Jul;53(7):e12854
pubmed: 32530555
Front Med (Lausanne). 2021 Feb 02;8:598076
pubmed: 33604347
Curr Rheumatol Rep. 2012 Oct;14(5):445-54
pubmed: 22855296
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Curr Opin Rheumatol. 2007 May;19(3):289-95
pubmed: 17414958
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436
Bone Res. 2018 Apr 27;6:15
pubmed: 29736302
Front Immunol. 2019 Jan 18;10:3
pubmed: 30713533
Expert Rev Clin Immunol. 2021 May;17(5):417-420
pubmed: 33706640
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Biochem Biophys Res Commun. 2001 Nov 9;288(4):841-3
pubmed: 11688984
RMD Open. 2021 Jun;7(2):
pubmed: 34112702
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
EMBO J. 2009 Jul 22;28(14):2114-27
pubmed: 19536133
Front Immunol. 2021 Aug 30;12:724895
pubmed: 34526997
J Orthop Translat. 2017 May 23;10:86-93
pubmed: 29662760
Arthritis Res Ther. 2012 Apr 11;14(2):R74
pubmed: 22494514
J Thorac Dis. 2015 Mar;7(3):E11-5
pubmed: 25922740
Front Immunol. 2011 Oct 10;2:52
pubmed: 22566842